Covagen begins Phase Ib/IIa study of anti-TNF/IL-17A FynomAb COVA322
The Phase Ib/IIa study will evaluate the safety, tolerability and pharmacokinetics of a single ascending dose of COVA322, a bispecific TNF/IL-17A inhibitor. The randomized, double-blind, placebo-controlled will enroll
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.